70-Gene signature-guided adjuvant systemic treatment adjustments in early-stage ER+ breast cancer patients: 7-year follow-up of a prospective multicenter cohort study.

Breast Cancer Res Treat · 2025 · PMC11785635 · PMID 39349887

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

borderline significantno p-value reported

The observed five percent DMFS difference in favor of the genomic low-risk group was borderline significant, and this was corroborated by a similar trend in DFS and OS.

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.